



# Lipophilicity – A Tale of 3 pHs

Ferdausi Mazumder

Physicochemical Analysis | Analytical Chemistry  
Molecular Modalities Capabilities (MMC) | Molecular Modalities Discovery (MMD) | Research Tech  
GSK, Stevenage

# Agenda

---

**1**

## **Introduction**

Drug Discovery Process  
ADME  
Physchem Props  
Lipophilicity – Then & Now

---

**2**

## **ChromlogD @ 3 pHs**

Why?  
How?  
PFI  
Acid/Base classification  
Comparison with pKa

---

**3**

## ***in silico* ChromlogD models**

How are they generated?  
How are they utilised?

---

**4**

## **Impact of ChromlogD**

LLE  
Optimizing PROTACs

---

**5**

## **Conclusion**


Key Messages

# 1 – Introduction


**GSK**

## ADME

One of the major causes of the high attrition rate in the drug industry is **poor ADME properties** which are influenced by Physchem properties.



# How do Physchem Properties influence ADME/Pharmacokinetics?




## Lipophilicity – The Key Drug-Like Property

Ability  
of a compound to  
dissolve in fats and  
non-polar solvents  
“Fat-liking”

Affects  
pharmacokinetic  
and  
pharmacodynamic  
behaviour.

Assessed by  
Octanol-  
Water Log P


Lipophilic  
molecules prefer  
lipid environments.  
Hydrophilic  
molecules prefer  
aqueous  
environments.



**LogP:** partition coefficient of the neutral form of the compound.

**LogD:** distribution coefficient of the ionised form of the compound, hence **pH dependent**

# What does lipophilicity (log P) affect?




So log P needs to be optimised

# Lipophilicity Measurements – Then and Now

## Octanol-Water LogP

The “gold standard” measurement of lipophilicity



# Lipophilicity Measurements – Then and Now

## Octanol-Water LogP

The “gold standard” measurement of lipophilicity



Doesn't cater for  
new chemical  
spaces



Requires  
more  
resources.



Issues with  
insoluble or highly  
lipophilic  
compounds.




Insufficient  
dynamic range.

## Lipophilicity Measurements – Then and Now

### Octanol-Water LogP

The “gold standard” measurement of lipophilicity

Measured vs Calculated OctanolLogD<sub>pH7.4</sub>



Data colour coded by measured kinetic aqueous solubility at pH7.4

Red < 30uM

Yellow 30-200uM

Green >200uM


Black line:  $y=x$

Blue line: regression line

# Lipophilicity Measurements – Then and Now

## Chromatographic LogD

### Chromatographic-based measurement of lipophilicity



Easily automated  
and high-  
throughput method



Robust and  
reliable



Covers a dynamic  
range  
(ChromlogD<sub>7.4</sub> -1 – 9)





Measured at  
various pHs

# 2 – Chromatographic LogD @ 3 pHs


**GSK**

# How is it measured?

Chromatographic retention ( $R_t$ ) on a non-polar stationary phase using aqueous mobile phase shows good correlation with compound's lipophilicity.




Retention time is converted to **Chromatographic Hydrophobicity Index (CHI)**



## 2 – ChromlogD @ 3 pHs

# How is it measured?



Compounds injected into HPLC alongside a **calibration test mix**

A calibration graph is produced at each pH.

**Retention time** is converted into a CHI value using calibration parameters.

CHI is converted to a log scale, **ChromlogD**

## 2 – ChromlogD @ 3 pHs

# Producing High-Quality Data: System Suitability Checks

	CHI PH2 Original	CHI PH2 this run	CHI PH7.4 Original	CHI PH7.4 this run	CHI PH10.5 Original	CHI PH10.5 this run	Acid/Base Character	Difference		
Carbamazepine	59.60	61.35	60.20	61.02	60.15	58.76	Neutral	1.75	0.82	-1.39
Budesonide	80.00	82.64	77.79	79.23	79.45	79.24	Neutral	2.64	1.44	-0.21
Warfarin	82.94	83.98	43.94	43.68	31.17	31.95	Acidic	1.04	-0.25	0.77
Ketoprofen	75.14	76.28	41.49	41.60	34.82	34.75	Acidic	1.13	0.11	-0.07
Indomethacin	90.47	91.82	55.30	56.08	48.12	47.06	Acidic	1.35	0.78	-1.06
Haloperidol	38.25	39.68	69.61	70.46	94.45	94.47	Basic	1.44	0.85	0.02
Chlorpromazine	43.52	46.54	85.48	87.24	127.64	128.11	Basic	3.02	1.76	0.47
Nicardipine	40.88	43.60	104.58	105.02	109.33	109.58	Basic (weak)	2.72	0.44	0.25

CHI data should be within +/- 5 of the original data

Calibration curve	CHI PH2 before	CHI PH2 after	CHI PH7.4 before	CHI PH7.4 after	CHI PH10.5 before	CHI PH10.5 after
Slope	122.38	121.90	109.72	109.79	121.88	122.21
Intercept	-44.27	-43.74	-34.22	-34.09	-43.50	-43.69
R2	0.9942	0.9943	0.9948	0.9949	0.9933	0.9933

R<sup>2</sup> should be greater than 0.985

### Why is it measured?

- ✓ Quick assessment of the **acid/base character** of a compound
- ✓ LogP of the unionised form
- ✓ **Lipophilic Ligand Efficiency (LLE)**
- ✓ Property Forecast Index (PFI)

$$LE = (1.37 \times \text{pIC}_{50})/\text{HA}$$

$$LLE = \text{pIC}_{50} - \text{LogP or LogD}$$

where HA is the number of heavy (nonhydrogen) atoms

$\text{pIC}_{50}$  is the activity/potency

## 2 – ChromlogD @ 3 pHs

Property Forecast Index (PFI) parameter forecasts potential developability issues

$$\text{PFI} = \text{ChromlogD}_{7.4} + \text{Number of Aromatic Rings}$$

Drug Discovery Today • Volume 16, Numbers 17/18 • September 2011

REVIEWS

TABLE 2

Percentages of compounds achieving defined target values in the various developability assays categorised by PFI or iPFI bins<sup>a</sup>

Assay / target value	PFI = mChrom log D <sub>pH7.4</sub> + #Ar								
	<3	3-4	4-5	5-6	6-7	7-8	8-9	9-10	>10
Solubility >200 μM	89	83	72	58	33	13	5	3	2
%HSA <95%	88	80	74	64	50	30	17	8	4
2C9 pIC <sub>50</sub> <5	97	90	83	68	48	32	23	22	38
2C19 pIC <sub>50</sub> <5	97	95	91	82	67	52	42	42	56
3A4 pIC <sub>50</sub> <5	92	83	80	75	67	60	58	61	66
Cl <sub>int</sub> <3 ml/min/kg	79	76	68	61	54	42	41	39	52
Papp >200 nm/s	20	30	46	65	74	77	65	50	33
	iPFI = mChrom log P + #Ar								
hERG pIC <sub>50</sub> <5 (+1 charge)	86	93	88	70	54	36	29	21	11
Promiscuity <5 hits with pIC <sub>50</sub> >5	85	78	74	65	49	30	20	13	7

<sup>a</sup> Colouring refers to the % chance of achieving benchmark value in that PFI bin: green, ≥67%; yellow, 34–67%; and red, <33%.

PFI <7 = less developability issues

Optimise ChromLogD7.4



Better PFI




Less Developability issues

# Acid/Base Classification

Compounds can be categorised using CHI values

- **Acid**
  - **Base**
  - **Weak Acid**
  - **Weak Base**
  - **Neutral**
  - **Amphoteric**
- **Prediction of Acid/Base character without the need of a structure**



# Comparison of Measured pKa with CHI Acid/Base Classification

Compound ref	Measured CHI			CHI Acid/Base Classification	Measured pKa*	
	pH 2.0	pH 7.4	pH 10.5		pKa (most acidic)	pKa (most basic)
1	9	49	47	Weak Base		7.0
2	28	51	51	Weak Base		4.0
3	16	36	67	Basic		10.0
4	17	39	83	Basic		9.9
5	94	91	73	Weak Acid	8.4	
6	66	63	44	Weak Acid	8.1	
7	100	58	52	Acidic	3.7	
8	81	54	47	Acidic	3.7	
9	46	63	53	Amphoteric	4.7	8.8
10	46	60	49	Amphoteric	4.6	9.2

\*pKa data measured using the Sirius T3 Titrator (manufactured by Pion)

# Comparison of Measured pKa with CHI Acid/Base Classification

Compound ref	CHI Acid/Base Classification	Measured pKa		Predicted pKa*	
		pKa (most acidic)	pKa (most basic)	pKa (most acidic)	pKa (most basic)
1	Weak Base		7.0		9
2	Weak Base		4.0		2.9
3	Basic		10.0		9.7
4	Basic		9.9		10.1
5	Weak Acid	8.4		9.6	
6	Weak Acid	8.1		9.9	
7	Acidic	3.7		2.9	
8	Acidic	3.7		3.1	
9	Amphoteric	4.7	8.8	3.6	8.8
10	Amphoteric	4.6	9.2	3.6	8.6

# 3 – *in silico* ChromlogD models






### 3 – *in silico* ChromlogD models

## How are they generated?

### GSK's "Predict First" Aspiration

- Predictive tools of the physchem properties using AI/ML
- *In-silico* models of ChromlogD at 3 pHs (2.0, 7.4, 10.5)
- Built in collaboration with our Computational Chemists using in house measured ChromlogD data



### 3 – *in silico* ChromlogD models

## How are they utilised?

#### WITHIN THE WIDER ORGANISATION

- Used to estimate properties of novel molecules
- Predict behaviour of compounds allowing potential liabilities to be addressed
- Ranking compounds

#### WITHIN THE PHYSCHEM TEAM


- Comparison of measured and predicted ChromlogD data
- Used for data validation by detecting anomalous data

#### PREDICT-FIRST

Generate



Predict

Select



### 3 – *in silico* ChromlogD models

## How are they utilised?




# 4 – Impact of ChromlogD measurements



## 4 – Impact of ChromlogD

# Progression of a Program Series using LLE







# 5 – Conclusions




# 5 – Conclusion

## Key Messages



**ATTRITION**



## 5 – Conclusion

# Acknowledgements

- Physchem Team UK (RHS)
- Analytical Chemistry, GSK UK
- Adrian Dunn, Informatics
- Sample Management
- Computational Chemistry
- Discovery Chemistry Teams
- Klara Valko
- Rob Young




Ferdousi Mazumder



Shenaz Bunally



Omar Rahman



Klis Ramdeen-Lessey



Paul Gurton



Rob Armstrong



**Thank you for listening!**

Any questions?

**GSK**

# Further Reading

- Veber D.F.; Johnson S.R.; Chen H-Y.; Smith B. R.; Ward K. W.; Kopple D. **Molecular properties that influence the oral bioavailability of drug candidates**, J. Med. Chem. 45, 2002, 2615-2623.
- Valko K.; Bevan C.; Reynolds D. **Chromatographic hydrophobicity index by fast-gradient RP-HPLC: A high-throughput alternative to logP/logD**. Anal. Chem., 69, 1997, 2022-2029.
- Robert J. Young, Darren V.S. Green, Christopher N. Luscombe, Alan P. Hill; **Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity** Drug Discovery Today, Volume 16, Issues 17–18, September 2011, Pages 822–830
- Valko K.; **Measurements of lipophilicity and acid/base character using HPLC methods**, In Pharmaceutical Profiling in Drug Discovery for Lead Selection, Eds Borchardt, R., Kerns, E., AAPS, Arlington, VA., pp127—182.
- Valko K.; Chau M. D.; Bevan C.; Abraham M. H.; Reynolds D. P. **Rapid Method for the Estimation of Octanol/Water Partition Coefficient (LogPoct) from Gradient RP-HPLC Retention and a Hydrogen Bond Acidity Term**, Current Med. Chem.8, 2001, 1137-1146.